Search a title or topic

Over 20 million podcasts, powered by 

Player FM logo
Artwork

Content provided by Dr Neil Love. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Dr Neil Love or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.
Player FM - Podcast App
Go offline with the Player FM app!

Chronic Lymphocytic Leukemia — An Interview with Dr Lindsey Roeker on Key Presentations from the 66th American Society of Hematology (ASH) Annual Meeting (Companion Faculty Lecture)

30:24
 
Share
 

Manage episode 484593885 series 1464352
Content provided by Dr Neil Love. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Dr Neil Love or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://podcastplayer.com/legal.

Featuring a slide presentation and related discussion from Dr Lindsey Roeker, including the following topics:

  • Recent clinical updates with standard regimens for chronic lymphocytic leukemia (CLL) (0:00)
  • Utility of minimal residual disease-guided treatment intensification after ibrutinib with venetoclax  (7:03)
  • Major long-term findings from the GLOW study of ibrutinib with venetoclax (10:35)
  • Principal findings from the AMPLIFY study of acalabrutinib with venetoclax with or without obinutuzumab (12:28)
  • Findings with combined acalabrutinib, venetoclax and obinutuzumab for patients with previously untreated high-risk disease  (15:52)
  • Early clinical findings with sonrotoclax and zanubrutinib as front-line treatment for CLL (18:12)
  • Principal findings from the BRUIN CLL-321 trial of pirtobrutinib for patients who previously received a covalent Bruton tyrosine kinase (BTK) inhibitor  (19:38)
  • Emerging evidence with pirtobrutinib, venetoclax and obinutuzumab as front-line treatment  (22:15)
  • Novel strategy combining lisocabtagene maraleucel with ibrutinib for relapsed/refractory (R/R) CLL (24:13)
  • Available data with epcoritamab monotherapy for R/R CLL  (26:58)
  • The emerging pharmacologic class of BTK degraders  (29:04)

CME information and select publications

  continue reading

1545 episodes

Artwork
iconShare
 
Manage episode 484593885 series 1464352
Content provided by Dr Neil Love. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Dr Neil Love or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://podcastplayer.com/legal.

Featuring a slide presentation and related discussion from Dr Lindsey Roeker, including the following topics:

  • Recent clinical updates with standard regimens for chronic lymphocytic leukemia (CLL) (0:00)
  • Utility of minimal residual disease-guided treatment intensification after ibrutinib with venetoclax  (7:03)
  • Major long-term findings from the GLOW study of ibrutinib with venetoclax (10:35)
  • Principal findings from the AMPLIFY study of acalabrutinib with venetoclax with or without obinutuzumab (12:28)
  • Findings with combined acalabrutinib, venetoclax and obinutuzumab for patients with previously untreated high-risk disease  (15:52)
  • Early clinical findings with sonrotoclax and zanubrutinib as front-line treatment for CLL (18:12)
  • Principal findings from the BRUIN CLL-321 trial of pirtobrutinib for patients who previously received a covalent Bruton tyrosine kinase (BTK) inhibitor  (19:38)
  • Emerging evidence with pirtobrutinib, venetoclax and obinutuzumab as front-line treatment  (22:15)
  • Novel strategy combining lisocabtagene maraleucel with ibrutinib for relapsed/refractory (R/R) CLL (24:13)
  • Available data with epcoritamab monotherapy for R/R CLL  (26:58)
  • The emerging pharmacologic class of BTK degraders  (29:04)

CME information and select publications

  continue reading

1545 episodes

Усі епізоди

×
 
Loading …

Welcome to Player FM!

Player FM is scanning the web for high-quality podcasts for you to enjoy right now. It's the best podcast app and works on Android, iPhone, and the web. Signup to sync subscriptions across devices.

 

Listen to this show while you explore
Play